AT-587 safety test in healthy adults
Official title: A Phase 1, First-in-Human (FIH), Single-center, Randomized, Double-blind, Placebo-controlled, Single and Multiple Ascending Dose Trial to Evaluate the Safety, Tolerability, and Pharmacokinetics (PK) of AT-587 in Healthy Adult Participants
Run by Atea Pharmaceuticals, Inc. · NCT07728487 · Data updated 2026-11-12
This study tests whether AT-587 is safe and how it behaves in the body of healthy adults.
Quick facts
| Phase | Phase 1 |
|---|---|
| Study type | Interventional |
| Ages | 18 Years to 65 Years |
| Sex | All |
| Enrollment | 62 (estimated) |
| Sponsor | Atea Pharmaceuticals, Inc. Industry-sponsored |
| Locations | 1 site (Edegem) |
| Status | Recruiting |
| Started | July 13, 2026 |
| Main results expected | December 2026 |
| Study ends | December 2026 |
| Registry record updated | July 27, 2026 |
| Trial ID | NCT07728487 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Healthy adults aged adults eligible by BMI 18-29 kg/m2, not pregnant or breastfeeding, and willing to follow contraception requirements and informed consent.
✕Probably not a fit
Participants with pregnancy, breastfeeding, recent use of other investigational drugs, or significant medical conditions may not benefit from the study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This is a Phase 1, first-in-human trial conducted at a single site to assess safety, tolerability, and pharmacokinetics of AT-587. It uses a randomized, double-blind, placebo-controlled design with both single and multiple ascending doses. The study will compare AT-587 to placebo in healthy adult participants who meet inclusion criteria and do not have exclusion conditions. The trial will monitor safety signals and PK parameters to determine suitable dosing for future studies.
Why it matters
Potential benefit: If successful, the study could support further development of AT-587 for patients with hepatitis E by establishing a safe starting dose and PK profile.
How similar studies have gone: Phase 1 first-in-human studies of similar antivirals have shown favorable safety and PK profiles in healthy volunteers, but this specific AT-587 study is an initial evaluation.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Body mass index (BMI) of 18-29 kg/m2 * Must agree to use protocol-specified methods of contraception * Negative pregnancy test * Willing to comply with the study requirements and to provide written informed consent Exclusion Criteria: * Pregnant or breastfeeding * Abuse of alcohol or drugs * Use of other investigational drugs within 30 days of dosing * Other clinically significant medical conditions
Where it's running
-
Atea Study Site
Edegem, Belgium Recruiting
Study contacts
- Study coordinator: Clinical Trials Administrator
- Email: AteaClinicalTrials@ateapharma.com
- Phone: 888-481-1607
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Community spread of multiple infectious diseases in Cambodia from a One Health perspective
This project will test how common and connected dengue, chikungunya, Zika, Japanese encephalitis, and West Nile infections are among people, animals, and the environment across Cambodia.
-
Entecavir 0.5 mg vs 1.0 mg daily in adults with HBV-related decompensated cirrhosis
This trial tests whether 0.5 mg or 1.0 mg of entecavir once daily can better lower HBV DNA in adults with HBV-related decompensated cirrhosis over 24 weeks.
-
Hepatitis B in Zambia: an observational cohort of adults with HBV, with or without HIV
This observational cohort follows adults diagnosed with hepatitis B in Zambia, with and without HIV coinfection, to see how their liver disease and HBV (and HIV when present) change over several years while they receive standard care.
-
Long-term outcomes of pegylated interferon alfa-2b in families with clustered hepatitis B and high risk of cirrhosis or liver cancer
This study will try pegylated interferon alfa-2b to see if it improves long-term outcomes for people with chronic hepatitis B from families where cirrhosis or liver cancer affects two generations.
-
Comparing two treatments to prevent hepatitis B transmission from mothers to infants
This study is testing whether two different antiviral treatments can help prevent pregnant women with high hepatitis B levels from passing the virus to their babies.
-
Untreated or Unknown HBV, HDV, and HCV in South-East Austria: See if People Need Care
This study looks at past test results to see how many people in South-East Austria have hepatitis B, hepatitis D coinfection, or hepatitis C that hasn’t been treated yet or isn’t known, and then invites them for care.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.